Tumor and Normal-Tissue Uptake of 111In-DTPA-Fab in SK-OV-3 Xenografts and 111In-DTPA-HRG in Mice with MDA-MB-468 Xenografts
| %ID/g | |||
| Tissue | 111In-DTPA-HRG in MDA-MB-468 (HER3+) | 111In-DTPA-Fab in SK-OV-3 (HER2+) | |
| Blood | 0.3 ± 0.1 | 1.0 ± 0.1 | |
| Heart | 0.5 ± 0.1 | 1.4 ± 0.1 | |
| Lung | 0.6 ± 0.3 | 1.6 ± 0.5 | |
| Liver | 1.1 ± 0.8 | 2.5 ± 0.4 | |
| Kidney | 7.1 ± 2.1 | 6.0 ± 2.0 | |
| Spleen | 1.3 ± 0.2 | 1.4 ± 3.1 | |
| Stomach | 1.0 ± 0.2 | 1.4 ± 0.1 | |
| Small intestines | 1.5 ± 0.3 | 0.8 ± 0.1 | |
| Large intestines | 1.5 ± 0.2 | 0.7 ± 0.1 | |
| Muscle | 0.9 ± 0.1 | 0.7 ± 0.1 | |
| Tumor | 2.1 ± 0.4 | 7.9 ± 1.5 | |
| Bladder | 1.2 ± 1.8 | 0.2 ± 0.2 | |
| Skin | 1.0 ± 0.3 | 0.3 ± 0.2 | |
| Tail | 1.7 ± 1.1 | 0.6 ± 0.2 | |
CD1 athymic mice were administered 35–40 MBq/10 μg of 111In-DTPA-Fab-PEG24-HRG (n = 3) and sacrificed at 48 h after injection. Data are mean ± SD.